ARTICLE | Strategy
Double dealing
March 22, 2004 8:00 AM UTC
Mitsubishi Pharma Corp. has now out-licensed the data package for its MCI-225 molecule twice, setting up what could be a patent battle somewhere down the road for the biotech companies that have licensed it. Both appear to be working in similar areas and both have filed patents.
Mitsubishi (Tokyo, Japan) originally partnered the small molecule reuptake inhibitor of noradrenaline and serotonin/selective serotonin (5-HT3) receptor antagonist with Dynogen Pharmaceuticals Inc. last December. But last week, Arachnova Therapeutics Ltd. announced a similar deal with Mitsubishi...